Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short- versus long-course maximal androgen deprivation with radiotherapy for locally advanced prostate cancer
ACTRN12607000237482Phase 3Completed
- Sponsor
- Trans-Tasman Radiation Oncology Group
- Start
- Jun 1996
- Modality
- Small Molecules, Peptides
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of goserelin and flutamide in prostate cancer (PCa) (3 arms), sponsored by Trans-Tasman Radiation Oncology Group. Primary endpoints: Cause specific survival and Overall survival. Started Jun 1996; status: completed.
02
Drugs
goserelinflutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ACTRN12607000237482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000237482.